StockWire X

StockWire X StockWire X is a mining-free digital publication delivering real-time investor news on ASX-listed tech, biotech, healthcare, industrials, and financials.

We help investors stay informed & give listed companies a smarter way to reach the right audience. Stock Wire X is Australia’s only investor news publication focused exclusively on non-mining ASX-listed companies. We deliver real-time, easy-to-understand updates on the companies shaping the future — across technology, biotech, healthcare, industrials, and financials. In a market saturated with min

ing headlines, we give investors and listed companies a smarter alternative. Whether you're an investor looking for clarity or a company wanting to reach the right audience, Stock Wire X is built for you.

👉 100% non-resource coverage
👉 Fast, factual, investor-focused news
👉 No mining. No fluff. Just the other side of the ASX.

A$110 million in consolidated funding with A$20-30M of headroom at seasonal peaks - that's the kind of financial flexibi...
24/06/2026

A$110 million in consolidated funding with A$20-30M of headroom at seasonal peaks - that's the kind of financial flexibility that turns growth ambitions into contracted revenue.

Schoolblazer Group has secured a conditional A$110 million global trade finance and term debt facility with Westpac Banking Corporation, replacing fragmented banking arrangements with a single integrated structure. The facility comprises A$45M in 5-year term debt and up to A$65M in seasonal trade finance that flexes with the Northern Hemisphere back-to-school cycle. Completion is expected prior to 30 June 2026, with the company reporting a material reduction in blended cost of debt compared to previous arrangements.

Executive Chairman Tim James explained: "Westpac's Education sector capability and global reach make them an ideal long-term partner as we grow our contracted school base across the UK, Australia, New Zealand and beyond. The unified facility simplifies our balance sheet, reduces our cost of debt and provides the funding capacity to execute on a sizeable global growth pipeline." The facility is secured against Schoolblazer Group assets with no recourse to the listed parent entity, and includes approximately A$20-30M of funding headroom at seasonal peaks to support expansion across the company's c.1,000 contracted schools globally.

Get the complete breakdown of the facility structure and growth strategy: https://stockwirex.com/asx-stock-news/industrials/sbz-schoolblazer-westpac-110m-facility-june-2026/

$26 million rental revenue and ~160% growth - that's the kind of trajectory that turns heads, even when a company's been...
24/06/2026

$26 million rental revenue and ~160% growth - that's the kind of trajectory that turns heads, even when a company's been in suspension for months.

Babylon Pump & Power has outlined a recapitalisation and debt refinancing package designed to support the resumption of trading in August 2026, anchored by a specialist water management rental business that's performing strongly despite balance sheet pressures. The Company expects FY26 rental revenue of approximately $26 million, up ~160% on FY25, with normalised rental segment EBITDA of $9.4m-$9.8m. The pressure on the balance sheet stems from weakness in the maintenance segment (driven by exposure to subdued Queensland coal) and an unsuccessful $60 million acquisition process, not the underlying rental business itself.

NAB has agreed to waive quarterly principal repayments for June and September 2026, reduce ongoing payments, and extend facility maturity to July 2027, subject to Babylon securing at least $3.5 million via an equity capital raise in August 2026. The Board is progressing a capital raise comprising unsecured convertible loans and a pro rata entitlement issue, with discussions underway for partial underwriting and substantial shareholder support already indicated. The Company continues working toward exiting the maintenance business during Q1 FY27, completing its transition to a pure-play water management rental platform with recurring revenues and improved earnings quality.

Get the complete analysis of what the recapitalisation means for the August trading resumption: https://stockwirex.com/asx-stock-news/industrials/bpp-babylon-pump-power-recapitalisation-plan-june-2026/

$4.8 million in annualised cost savings while maintaining $65 million in monthly recurring payments - that's how you exe...
24/06/2026

$4.8 million in annualised cost savings while maintaining $65 million in monthly recurring payments - that's how you execute a strategic turnaround without breaking the business.

Spenda has delivered approximately $400,000 per month in combined cost reductions since 1 May 2026, spanning headcount optimisation, contractor arrangements and reduced infrastructure spend. The cuts are surgical rather than blunt - no changes to product availability or service delivery, with AI integration now supporting automation and scalability. Monthly recurring payments transaction volume holds steady at $65 million, and the company has secured 10 new Carpet Court retail stores receiving SaaS fees from head office.

The Board is now reviewing multiple pathways to value creation, including balance sheet recapitalisation, potential acquisitions to complement the embedded finance platform, and emerging opportunities in quantum-secure financial infrastructure. The Ledger platform divestment to APG Pay earlier in May contributed an additional $2.7 million in annual savings, bringing total annualised savings across the five-month program to approximately $7 million. The leaner cost base directly improves profitability potential across Spenda's layered revenue streams from SaaS, B2B/B2C payments and supply chain finance.

Get the full breakdown of the strategic review and what comes next: https://stockwirex.com/asx-stock-news/tech-ai/spx-spenda-limited-cost-cuts-turnaround-june-2026/

A 6.8-point drop in depression scores among treatment-resistant patients — that's the kind of early signal that validate...
23/06/2026

A 6.8-point drop in depression scores among treatment-resistant patients — that's the kind of early signal that validates a clinical model's expansion into a second major indication.

Emyria has reported encouraging early data from the first cohort of 10 patients in its treatment-resistant depression (TRD) program, with depression symptoms falling from 16.8 to 10.0 on the QIDS-SR16 scale. Every patient showed statistically significant improvements across all four standard mental health measures, including depression severity, trauma symptoms, quality of life, and daily functioning. The results are being presented at the 2026 International Mental Health Conference and mark the Company's second major treatment program delivered through its national Empax Centre network.

Chief Scientific Officer Dr Michael Winlo explained: "Every patient in our first depression cohort analysed demonstrated significant improvements across depression and trauma symptoms, quality of life and everyday functioning. This is especially encouraging given these are individuals who were previously living with treatment-resistant depression, a major unmet need in mental health." The TRD program follows the same real-world data collection approach used in Emyria's established PTSD program, where 67% of treatment-resistant patients maintained clinical remission at 12 months post-treatment. With a fifth clinic preparing to come online in Q3 2026 and most patients supported by private health insurance or major health funders, the program is scaling into a market of approximately 600,000 Australians affected by treatment-resistant depression.

Read the full analysis of the clinical data and national expansion timeline: https://stockwirex.com/asx-stock-news/biotech-health/emd-emyria-depression-treatment-results-june-2026/

The Queensland Competition Authority has released its preliminary assessment of Aurizon's UT5+ regulatory framework — an...
23/06/2026

The Queensland Competition Authority has released its preliminary assessment of Aurizon's UT5+ regulatory framework — and the material part has been endorsed as appropriate.

The QCA's draft decision marks significant progress toward final approval of the 10-year access undertaking governing the Central Queensland Coal Network from 1 July 2027 to 30 June 2037. Key elements endorsed include the Weighted Average Cost of Capital methodology, accelerated depreciation profile, and throughput payment structure. The only outstanding matter relates to the proposed operating expenditure allowance, which the QCA has flagged for further stakeholder submissions by 20 August 2026.

For investors, this preliminary endorsement provides near-term regulatory certainty around the pricing and access framework that will govern Aurizon's regulated network business for the next decade. The defined pathway to final approval removes ambiguity, with the bulk of the commercial terms already receiving preliminary QCA support. Stakeholder submissions close in August, positioning UT5+ for final determination later this year.

Read the full regulatory breakdown and timeline implications: https://stockwirex.com/asx-stock-news/industrials/azj-aurizon-holdings-ut5-qca-regulatory-assessment-june-2026/

244 patients, two primary endpoints, and an independent board just recommended Avecho's Phase III insomnia trial continu...
23/06/2026

244 patients, two primary endpoints, and an independent board just recommended Avecho's Phase III insomnia trial continue to full enrollment — that's the clinical validation biotech investors wait years to see.

Avecho Biotechnology's CBD insomnia trial cleared its interim analysis with a dual win: treatment effect on at least one primary endpoint plus zero serious adverse events across 244 participants. The independent Data Monitoring Board recommended continuing to the originally planned 519-patient cohort rather than increasing sample size, signaling the product's effect size and safety profile are tracking at or better than the assumptions used to design the trial. Those assumptions held that the CBD TPM® capsule performs as well as approved insomnia drugs.

The commercial context adds weight to the clinical signal. Sandoz has already locked in US$19M in upfront and milestone payments plus 14–19% tiered royalties for Australian rights, with management positioning Australia as the first territory in a global licensing strategy. The TGA's Schedule 3 OTC pathway permits CBD ≤150mg/day for pharmacist-only sale, but no product has yet met the efficacy bar for ARTG registration. A positive Phase III is the registration-enabling dataset for a market Avecho sizes at >US$125M per annum in Australia alone, with the global insomnia market projected to hit US$9.5bn by 2033.

Read the full interim analysis breakdown and TGA submission timeline: https://stockwirex.com/asx-stock-news/biotech-health/ave-avecho-biotechnology-phase-iii-cbd-results-june-2026/

Baby Bunting just guided to $16.0m-$17.0m profit for FY26 - a 32% to 40% jump on last year - but missed its own second-h...
23/06/2026

Baby Bunting just guided to $16.0m-$17.0m profit for FY26 - a 32% to 40% jump on last year - but missed its own second-half forecast by nearly $2m at the midpoint.

The retailer expects full-year pro forma NPAT of approximately $16.0m to $17.0m, up sharply on FY25's $12.1m, with total sales around $553m-$555m (up ~6.0%) and comparable store sales growth of ~3.5%. However, second-half NPAT is now expected at $11.0m-$12.0m, below the previously guided range of $12.5m-$14.5m, after Q4 trading softened across non-refurbished stores. The weakness was concentrated in prams and car safety categories, which lowered average transaction values.

CEO Mark Teperson explained: "While trading softened through the fourth quarter, delivering pro forma NPAT growth of 32% to 40% for the full year and further gross margin expansion is a strong result in a difficult consumer environment." The "Store of the Future" program continues to deliver, with refurbished stores posting ~18% sales growth for FY26 (around 16% in 2H), while the online channel grew ~16% and New Zealand sales jumped above 15% in the second half. Gross margin is expected above 41% (~41.5% in 2H), up from 40.2% in FY25, with net debt at approximately $20m.

Read the full breakdown of what drove the Q4 miss and the strategic levers for FY27: https://stockwirex.com/asx-stock-news/consumer-discretionary/bbn-baby-bunting-group-fy26-trading-update-june-2026/

~A$75m to lock in Tier-1 LNG clients and recurring revenue - Tasmea's latest acquisition targets the structural energy s...
23/06/2026

~A$75m to lock in Tier-1 LNG clients and recurring revenue - Tasmea's latest acquisition targets the structural energy services opportunity.

In its June 2026 investor presentation, Tasmea outlined the acquisition of 100% of JPS Group for up to ~A$75m, comprising ~A$50m upfront (cash and scrip) plus earn-outs of up to A$25m across FY27-FY30. JPS brings an embedded workforce of ~150 FTE serving Chevron, Shell, Woodside, Santos and other majors across Australia's LNG infrastructure, with >80% revenue visibility in FY27e and FY26e EBIT of ~A$10m. Settlement is targeted for 1 August 2026 subject to ACCC approval, with the deal forecast to be ~5% EPS accretive in FY26e.

The strategic angle positions JPS as a platform for cross-selling Tasmea's specialist trades into long-term Master Service Agreements with Australia's 10 producing LNG facilities, which represent A$300bn+ in capex and mandatory recurring maintenance demand. Management retained all five Founder-GMs and highlighted JPS's sole Australian distribution rights for DBB Saver Technology, enabling maintenance while plants stay online. Combined with the earlier Maxim Group acquisition, pro forma FY26e underlying EBIT rises to A$185m with gearing at ~0.85x, positioning Tasmea for structural exposure to LNG, data centres and major infrastructure.

Read the full deal breakdown and synergy analysis: https://stockwirex.com/asx-stock-news/industrials/tea-tasmea-jps-group-acquisition-lng-june-2026/

Hospital approval in a major Bangkok teaching hospital - that's the kind of institutional access that opens the door to ...
23/06/2026

Hospital approval in a major Bangkok teaching hospital - that's the kind of institutional access that opens the door to clinical adoption at scale.

Osteopore has secured approval for its neurosurgery products at Thammasat University Hospital, a major tertiary care centre in Bangkok averaging 4,000 outpatient visits per day and operating over 800 inpatient beds. The milestone follows the appointment of Peakmed as the Company's exclusive Thai distributor in May 2025, establishing a pathway for its 3D-printed bioresorbable implants to reach surgeons treating brain tumour patients and performing craniotomy procedures. The technology allows natural bone regeneration as the scaffold dissolves, reducing complications associated with permanent implants.

TUH's credentials matter here - it's an Advanced Healthcare Accreditation-designated hospital and teaching centre for Thammasat University's Faculty of Medicine, with a neurosurgery division accredited by the Royal College of Neurological Surgeons of Thailand. The broader Thai market opportunity is substantial, with 93,810 brain tumour patients admitted over a 10-year period and a medical device market valued at US$19.93 billion. Osteopore is replicating its capital-efficient distributor model from China, where the Majeton partnership secured access to 13,500 hospitals without requiring an independent salesforce.

Get the full breakdown of Thailand's neurosurgery market opportunity and what this means for clinical adoption: https://stockwirex.com/asx-stock-news/biotech-health/osx-osteopore-neurosurgery-approval-thailand-june-2026/

A$75 million for a business delivering 5% EPS accretion immediately — that's the kind of acquisition math that gets inst...
23/06/2026

A$75 million for a business delivering 5% EPS accretion immediately — that's the kind of acquisition math that gets institutional attention.

Tasmea Limited has executed a Share Purchase Agreement to acquire 100% of JPS Group, a leading integrated services provider to Australia's LNG and critical energy infrastructure sector, for up to A$75 million. The deal structure splits into approximately A$50 million upfront (A$24.5m cash plus A$25.6m in Tasmea scrip) and up to A$25 million in performance-based earn-outs across FY27–FY30, contingent on JPS hitting a Maintainable EBIT target of ≥ A$12 million per annum. The upfront enterprise value implies an EV/EBIT multiple of approximately 5x on JPS FY26e Underlying EBIT of approximately A$10 million, with the transaction forecast to deliver approximately 5% pro forma EPS accretion in FY26e.

Managing Director Stephen Young explained: "The acquisition of JPS Group is a defining step in Tasmea's programmatic growth strategy and diversifies the Group's earnings into the structurally growing LNG, gas and critical energy infrastructure sectors." JPS brings Tier-1 client exposure across Chevron, ConocoPhillips, Shell, Santos and Woodside, with more than 10 long-term Master Services Agreements delivering revenue visibility in excess of 80% for FY27e. All five founder-General Managers are staying on long-term employment contracts and taking equity in Tasmea, preserving the owner-led model while unlocking access to Tasmea's balance sheet and 28-brand specialist services group. Settlement is targeted for on or around 1 August 2026, subject to customary conditions including ACCC approval, with JPS earnings contributing from FY27.

Get the complete deal structure breakdown, integration timeline and pro forma financials: https://stockwirex.com/asx-stock-news/industrials/tea-tasmea-jps-group-acquisition-june-2026/

Address

202/37 Barrack Street
Perth, WA
6000

Website

Alerts

Be the first to know and let us send you an email when StockWire X posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category